Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch ? First of three planned Phase 3 azetukalner MDD studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback